Questions: Portal Hypertension: Complications and Outcomes

Question 1

A medical student observes that a cirrhotic patient develops massive ascites despite having near-normal serum albumin and only mildly elevated portal pressure. The student concludes the ascites must have a different cause than portal hypertension. What does this case actually illustrate?

• A. The student is correct — ascites in cirrhosis requires low albumin and is not caused by portal pressure alone
• B. Ascites develops through a multi-factor pathway: portal hypertension triggers splanchnic vasodilation, which activates RAAS and renal sodium retention — portal pressure elevation alone is not the complete mechanism
• C. Portal hypertension is sufficient to cause ascites at any level above 10 mmHg, so the portal pressure must have been underestimated
• D. Ascites in this patient is caused by hepatic encephalopathy diverting fluid into the peritoneal cavity

Answer: (B)

The key insight is that ascites is not simple hydraulic overflow from high portal pressure. The sequence is: portal hypertension → nitric oxide overproduction → splanchnic vasodilation → reduced effective circulating volume sensed by kidneys → RAAS and ADH activation → renal sodium and water retention → expansion of total body fluid volume that preferentially pools in the peritoneum. Near-normal albumin merely reduces one contributing factor; the hemodynamic cascade can still drive ascites. This multi-factorial mechanism explains why treatment targets RAAS (diuretics, aldosterone antagonists) rather than just portal pressure.

Question 2

In hepatorenal syndrome, the kidneys fail to maintain adequate filtration despite being structurally normal. What is the mechanism?

• A. Ammonia accumulating in portal blood directly damages the renal tubular epithelium over time
• B. Portal hypertension creates direct venous back-pressure in the renal veins, obstructing glomerular filtration
• C. Severe splanchnic vasodilation pools blood in the gut circulation, reducing effective renal perfusion — the kidneys perceive themselves as volume-depleted despite total body fluid excess
• D. Bacterial translocation from the gut triggers an immune complex deposition in the glomeruli

Answer: (C)

Hepatorenal syndrome is the diagnostic puzzle of advanced portal hypertension: the kidneys are structurally and histologically normal (they will recover function in a transplanted patient), yet they fail to filter. The mechanism is that splanchnic vasodilation is so extreme that despite total body fluid overload, the kidneys receive inadequate perfusion — the renin-angiotensin system interprets the splanchnic pooling as hypovolemia and vasoconstricts the renal vasculature further. This distinguishes hepatorenal syndrome from intrinsic renal disease and explains why it can be reversed by liver transplantation.

Question 3

Esophageal varices rupture risk increases as varices enlarge, partly because Laplace's law predicts that a larger radius requires less transmural pressure to exceed wall tension.

• T. True
• F. False

Answer: True

Laplace's law states that wall tension = pressure × radius (simplified for a cylindrical vessel). This means that as a varix grows larger, the same portal pressure generates greater wall tension — and a smaller pressure increment is needed to rupture it. This is why variceal size is an independent predictor of bleeding risk, and why prophylactic treatment (beta-blockers to reduce portal pressure, band ligation to reduce variceal size) is initiated before the first bleed in large varices.

Question 4

Portal hypertension and cirrhosis are synonymous — most patient with cirrhosis has portal hypertension, and nearly every patient with portal hypertension has cirrhosis.

• T. True
• F. False

Answer: False

Both directions of this equivalence are false. Not all cirrhotic patients have clinically significant portal hypertension early in disease (portal pressure may be mildly elevated but below the threshold for variceal formation). More importantly, portal hypertension can occur without cirrhosis: portal vein thrombosis, Budd-Chiari syndrome (hepatic vein obstruction), schistosomiasis, and other causes create portal hypertension through mechanisms other than hepatic fibrosis. Recognizing non-cirrhotic portal hypertension matters clinically because the prognosis and management differ substantially.

Question 5

Explain why diuretic therapy (specifically aldosterone antagonists like spironolactone) is a mechanistically rational treatment for cirrhotic ascites, rather than simply 'draining' the portal hypertension.

Model answer: Cirrhotic ascites is not simply fluid overflowing from elevated portal pressure — it involves RAAS activation caused by the splanchnic vasodilation that portal hypertension triggers. The kidneys perceive reduced effective circulating volume and retain sodium and water via aldosterone. Spironolactone blocks aldosterone at the kidney, reducing renal sodium retention and correcting the fluid accumulation at its hormonal source rather than just treating the portal pressure. This is why diuretics targeting the RAAS are first-line therapy: they address the mechanism driving fluid retention.

The distinction matters because it illustrates that portal hypertension's complications are systemic, not local. Treating the portal pressure directly (e.g., with TIPS) can reverse ascites, but understanding why diuretics work requires grasping the neurohumoral cascade. Spironolactone's target is aldosterone, whose excess reflects the kidney's misinterpretation of body fluid status — fixing the hormonal signal corrects the fluid retention even without changing the portal pressure itself.